Premium
PITUITARY FUNCTION FOLLOWING MEGAVOLTAGE THERAPY FOR CUSHING'S DISEASE: LONG TERM FOLLOW UP
Author(s) -
SHARPE G. F.,
KENDALLTAYLOR P.,
PRESCOTT R. W. G.,
ROSS W. M.,
DAVISON C.,
WATSON M. J.,
COOK D. B.
Publication year - 1985
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1985.tb01078.x
Subject(s) - hypopituitarism , medicine , endocrinology , prolactin , cushing's disease , basal (medicine) , disease , hormone , insulin
SUMMARY Eight patients who had received megavoltage therapy for Cushing's disease 5–12 years previously have been reviewed. The long term response to this therapy was assessed with respect to efficacy of treatment in inducing continued remission and disturbance of hypothalamic‐pituitary function. One patient showed clear evidence of relapse of Cushing's disease. One patient had unequivocal hypopituitarism. Basal levels of growth hormone (GH), TSH, LH, and FSH were not statistically different from controls, but provocative testing revealed significant abnormalities of response of cortisol/ACTH, GH, prolactin and LH. Six out of eight patients had absent diurnal cortisol variation and five patients had elevated serum prolactin levels. Thus, in this group of patients normal pituitary‐adrenal function has not been satisfactorily restored. It is clear that significant disturbances of hypothalamic‐pituitary function follow mega‐voltage therapy and these may progress to overt hypopituitarism.